Pain response, neonates, and venipuncture

2022 ◽  
pp. 265-273
Author(s):  
Hardeep Kaur ◽  
Gaurav Mahajan
Keyword(s):  
Pain Response

Silica Incorporation in the Cell Wall of the Singing Cell of Urtica dioica

1975 ◽  
Vol 33 ◽  
pp. 584-585
Author(s):  
A. E. Sowers ◽  
E. L. Thurston
Keyword(s):  
Cell Wall ◽  
Unique Feature ◽  
Urtica Dioica ◽  
Wall Material ◽  
Pain Response ◽  
Apical Portion ◽  
Ultrastructural Investigation ◽  
Plant Families ◽  
Bulbous Tip

Plant stinging emergences exhibit functional similarities in that they all elicit a pain response upon contact. A stinging emergence consists of an elongated stinging cell and a multicellular pedestal (Fig. 1). A recent ultrastructural investigation of these structures has revealed the ontogeny and morphology of the stinging cells differs in representative genera in the four plant families which possess such structures. A unique feature of the stinging cell of Urtica dioica is the presence of a siliceous cell wall in the apical portion of the cell. This rigid region of the cell wall is responsible for producing the needle-like apparatus which penetrates the skin. The stinging cell differentiates the apical bulbous tip early in development and the cell continues growth by intercalary addition of non-silicified wall material until maturity.The uppermost region of the stinging cell wall is entirely composed of silica (Fig. 2, 3) and upon etching with a 3% solution of HF (5 seconds), the silica is partially removed revealing the wall consisting of individualized silica bodies (Fig. 4, 5).

Pain Response Inventory for Children

1997 ◽  
Author(s):  
Lynn S. Walker ◽  
Craig A. Smith ◽  
Judy Garber ◽  
Deborah A. Van Slyke
Keyword(s):  
Pain Response

Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP

2016 ◽  
Vol 55 (05) ◽  
pp. 188-195 ◽  
Author(s):  
Floor Overbeek ◽  
John de Klerk ◽  
Pieternel Pasker-de Jong ◽  
Alexandra van den Berk ◽  
Rob ter Heine ◽  
...  
Keyword(s):  
Bone Metastases ◽  
Clinical Benefit ◽  
Response Rate ◽  
Clinical Care ◽  
Pain Response ◽  
Pain Palliation ◽  
Breast Cancer Patients ◽  
Routine Clinical Care ◽  
Painful Bone Metastases

Summary Aim: Rhenium-188-HEDP (188Re-HEDP) is an effective radiopharmaceutical for the palliative treatment of osteoblastic bone metastases. However, only limited data on its routine use are available and its effect on quality of life (QoL) has not been studied. Therefore, we evaluated the clinical benefit of 188Re-HEDP in routine clinical care. Patients and methods: Prostate or breast cancer patients with painful bone metastases receiving 188Re-HEDP as a routine clinical procedure were eligible for evaluation. Clinical benefit was assessed in terms of efficacy and toxicity. Pain palliation and QoL were monitored using the visual analogue scale (VAS), corrected for opioid intake, and the EORTC QLQ-C30 Global health status/QoL-scale. Thrombocyte and leukocyte nadirs were used to assess haematological toxicity. Results: 45 and 47 patients were evaluable for pain palliation and QoL, respectively. After a single injection of 188Re-HEDP, the overall pain response rate was 69% and mean VAS-scores decreased relevantly and significantly (p < 0.05). Repeated treatment resulted in similar pain response. The overall QoL response rate was 68% and mean Global health status/QoL-scores increased relevantly and significantly. Haematological side effects were mild and transient. Conclusion: The clinically relevant response on pain and quality of life and the limited adverse events prove clinical benefit of treatment with 188Re-HEDP and support its use in routine clinical care. Its effectiveness appears comparable to that of external beam radiotherapy.

Prenatal Pregabalin Exposure Alters Postnatal Pain Sensitivity and Some Behavioral Responses in Adult Offspring Rats

2020 ◽  
Vol 15 (3) ◽  
pp. 205-214
Author(s):  
Manzumeh-Shamsi Meymandi ◽  
Gholamreza Sepehri ◽  
Amirhossein Moslemizadeh ◽  
Seyyed Sajjad Vakili Shahrbabaki
Keyword(s):  
Locomotor Activity ◽  
Open Field ◽  
Prenatal Exposure ◽  
Pain Sensitivity ◽  
Sucrose Preference ◽  
Pain Response ◽  
Adult Offspring ◽  
Hot Plate ◽  
Hot Plate Test ◽  
Plate Test

Background: Prenatal antiepileptic drug exposure could demonstrate both congenital malformations and behavioral impairments in offspring. Objective: This study was performed to assess the effects of prenatal exposure to pregabalin (PGB) on pain response, anxiety, motor activity and some behavior of adult offspring rats. Methods: Pregnant Wistar rats received PGB (7.5, 15 and 30 mg/kg/ip) during embryonic days 9.5- 15.5. The pain response, anxiety-like behaviors, locomotor activity, motor balance and coordination and anhedonia of adult offspring were examined by tail-flick and hot plate test, open field test, elevated plus maze (EPM), beam balance test and sucrose preference test in their 60th day of life, respectively. Results: Prenatal exposure to PGB revealed significant dose-dependent reduction in pain sensitivity (increase in pain latency response) in the hot plate test, especially in females, while anxiety-like behavior assessed in EPM and open field significantly reduced in males. In the open field, locomotor activity reduced significantly after exposure to PGB 30 mg/kg and motor coordination decreased dose-dependently, especially in males. Anhedonia, as an indication of sucrose preference or pleasure response, was not changed. Conclusion: These findings suggest that prenatal PGB exposure could be associated with significant changes in pain response, anxiety, locomotor activity and coordination in adult offspring rats.

Chemo- and Optogenetic Strategies for the Elucidation of Pain Pathways

2019 ◽  
pp. 816-832 ◽  
Author(s):  
Sascha R. A. Alles ◽  
Anne-Marie Malfait ◽  
Richard J. Miller
Keyword(s):  
Chronic Pain ◽  
Pain Response ◽  
Conscious Perception ◽  
Novel Therapies ◽  
The Past ◽  
Nociceptive Pathways ◽  
Pain Pathways ◽  
Technical Advances ◽  
The Brain

Pain is not a simple phenomenon and, beyond its conscious perception, involves circuitry that allows the brain to provide an affective context for nociception, which can influence mood and memory. In the past decade, neurobiological techniques have been developed that allow investigators to elucidate the importance of particular groups of neurons in different aspects of the pain response, something that may have important translational implications for the development of novel therapies. Chemo- and optogenetics represent two of the most important technical advances of recent times for gaining understanding of physiological circuitry underlying complex behaviors. The use of these techniques for teasing out the role of neurons and glia in nociceptive pathways is a rapidly growing area of research. The major findings of studies focused on understanding circuitry involved in different aspects of nociception and pain are highlighted in this article. In addition, attention is drawn to the possibility of modification of chemo- and optogenetic techniques for use as potential therapies for treatment of chronic pain disorders in human patients.

scholarly journals Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib

RMD Open ◽  
2021 ◽  
Vol 7 (2) ◽  
pp. e001609
Author(s):  
Kurt de Vlam ◽  
Alexis Ogdie ◽  
Andrew G Bushmakin ◽  
Joseph C Cappelleri ◽  
Roy Fleischmann ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Median Time ◽  
Pain Severity ◽  
Visual Analogue Scale Pain ◽  
Pain Response ◽  
Link Type ◽  
Kaplan Meier ◽  
Analogue Scale Pain ◽  
The Impact ◽  
Pain Improvement

BackgroundPain is a core domain of psoriatic arthritis (PsA). This post hoc analysis evaluated time to pain improvement and the impact of baseline pain severity on pain response in patients with PsA receiving tofacitinib.MethodsData from two trials (NCT01877668; NCT01882439) in patients receiving tofacitinib 5 mg twice daily, placebo switching to tofacitinib 5 mg twice daily at month 3 (placebo-to-tofacitinib) or adalimumab (NCT01877668 only) were included. Improvement in pain (≥30%/≥50% decrease from baseline in Visual Analogue Scale pain score) was assessed; median time to initial (first post-baseline visit)/continued (first two consecutive post-baseline visits) pain improvement was estimated (Kaplan-Meier) for all treatment arms. A parametric model was used to determine the relationship between baseline pain severity and time to pain response in patients receiving tofacitinib.ResultsAt month 3, more patients experienced pain improvements with tofacitinib/adalimumab versus placebo. Median days (95% CI) to initial/continued pain improvements of ≥30% and ≥50%, respectively, were 55 (29–57)/60 (57–85) and 85 (57–92)/171 (90–not estimable (NE)) for tofacitinib, versus 106 (64–115)/126 (113–173) and 169 (120–189)/NE (247–NE) for placebo-to-tofacitinib. Pain improvements were also experienced more quickly for adalimumab versus placebo. Predicted time to ≥30%/≥50% pain improvement was shorter in patients with higher baseline pain versus lower baseline pain (tofacitinib arm only).ConclusionsIn patients with PsA, pain improvements were experienced by more patients, and more rapidly, with tofacitinib and adalimumab versus placebo. In those receiving tofacitinib, higher baseline pain was associated with faster pain improvements.

Acute experimentally-induced pain replicates the distribution but not the quality or behaviour of clinical appendicular musculoskeletal pain. A systematic review

2020 ◽  
Vol 0 (0) ◽  
Author(s):  
Brendon Ford ◽  
Mark Halaki ◽  
Joanna Diong ◽  
Karen A Ginn
Keyword(s):  
Systematic Review ◽  
Musculoskeletal Pain ◽  
Full Text ◽  
Experimental Pain ◽  
Common Mechanism ◽  
Mcgill Pain Questionnaire ◽  
Pain Response ◽  
Provocation Testing ◽  
Experimentally Induced

AbstractObjectivesExperimental pain is a commonly used method to draw conclusions about the motor response to clinical musculoskeletal pain. A systematic review was performed to determine if current models of acute experimental pain validly replicate the clinical experience of appendicular musculoskeletal pain with respect to the distribution and quality of pain and the pain response to provocation testing.MethodsA structured search of Medline, Scopus and Embase databases was conducted from database inception to August 2020 using the following key terms: “experimental muscle pain” OR “experimental pain” OR “pain induced” OR “induced pain” OR “muscle hyperalgesia“ OR (“Pain model” AND “muscle”). Studies in English were included if investigators induced experimental musculoskeletal pain into a limb (including the sacroiliac joint) in humans, and if they measured and reported the distribution of pain, quality of pain or response to a provocation manoeuvre performed passively or actively. Studies were excluded if they involved prolonged or delayed experimental pain, if temporomandibular, orofacial, lumbar, thoracic or cervical spine pain were investigated, if a full text of the study was not available or if they were systematic reviews. Two investigators independently screened each title and abstract and each full text paper to determine inclusion in the review. Disagreements were resolved by consensus with a third investigator.ResultsData from 57 experimental pain studies were included in this review. Forty-six of these studies reported pain distribution, 41 reported pain quality and six detailed the pain response to provocation testing. Hypertonic saline injection was the most common mechanism used to induce pain with 43 studies employing this method. The next most common methods were capsaicin injection (5 studies) and electrical stimulation, injection of acidic solution and ischaemia with three studies each. The distribution of experimental pain was similar to the area of pain reported in clinical appendicular musculoskeletal conditions. The quality of appendicular musculoskeletal pain was not replicated with the affective component of the McGill Pain Questionnaire consistently lower than that typically reported by musculoskeletal pain patients. The response to provocation testing was rarely investigated following experimental pain induction. Based on the limited available data, the increase in pain experienced in clinical populations during provocative maneuvers was not consistently replicated.ConclusionsCurrent acute experimental pain models replicate the distribution but not the quality of chronic clinical appendicular musculoskeletal pain. Limited evidence also indicates that experimentally induced acute pain does not consistently increase with tests known to provoke pain in patients with appendicular musculoskeletal pain. The results of this review question the validity of conclusions drawn from acute experimental pain studies regarding changes in muscle behaviour in response to pain in the clinical setting.

166: Does penile ring block anesthesia make a difference in pain response to Neonatal circumcision?

2012 ◽  
Vol 206 (1) ◽  
pp. S87
Author(s):  
Thomas Toussaint ◽  
Clones Lans ◽  
Douglas Sherlock ◽  
Joshua Fogel ◽  
Chaur-Dong Hsu
Keyword(s):  
Pain Response ◽  
Neonatal Circumcision
Sign in / Sign up

Export Citation Format

Share Document